A Phase 1/2 interventional study of Posiphen and Placebo in Alzheimer Disease and Parkinson Disease, sponsored by Annovis Bio Inc.. Completed at 13 sites in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.
Sponsored by Annovis Bio Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 792nd largest by enrollment of the 1,609 interventional ones that give a count, is one of 104 that started in 2020, is one of 67 in phase 1/2, and was the 1,230th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,940 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 104 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is close to the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,609 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,940 have an industry lead sponsor. The 10 most frequent:
Annovis Bio Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Annovis Bio Inc. has 6 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,940 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study. In Part one of the study Investigators will recruit 14 AD and 14 PD patients who will either receive placebo (an inert pill which looks like the study drug) or the study drug Posiphen, both taken daily. In Part two of the study Investigators will recruit 40 PD patients who will receive different strengths of the study drug Posiphen taken daily. Patients will be required to come to the site for 3 face to face visits and have 4 phone calls, tests include but are not limited to, blood and CSF (spinal fluid) sampling, cognitive assessments, clinical examinations and laboratory safety tests. Primarily the Investigators are looking for the safety and tolerability of Posiphen, although Investigators will also evaluate the activity of Posiphen by a number of different biomarkers measuring pathway and target engagements.
Part 1 is a study with 14 Early AD and 14 Early PD patients who are randomized to 80 mg of Posiphen or placebo. Participants will undergo a Screening Visit, provide informed consent and be evaluated for eligibility per the inclusion and exclusion criteria. If enrolled, participants will proceed to the randomized treatment portions of the study. Period 1 consists of first-time dosing in clinic with administration of 80 mg of Posiphen or Placebo. Period 2 consists of an at home dosing period of 25±2 days, with daily administration of 80 mg of Posiphen or Placebo. Period 3 will be comprised of a stay at the clinical research unit where the subject will undergo study procedures that include safety assessments (AE and concomitant medication monitoring, 12-lead ECGs, clinical laboratory testing, vital signs assessments, and physical examinations), the last dose of Posiphen or Placebo, and 6 hours of blood and CSF sampling. At the end of blood/CSF sampling, the subjects will need to stay for a minimum of 1 hour of observation but may stay if necessary for observation until the following day (e.g., if the subject has blood/CSF sampling on Day 25, he/she may stay for observation until Day 26). After all end-of-study procedures are complete, the subject will be discharged to home. A 24-hour follow-up call will occur to assess the participants current condition and if there are any additional adverse events to report.
After completion of Part 1 of the study, the plasma and CSF samples will be analyzed for the biomarkers to determine if changes are needed to the biomarkers to be measured in Part 2. Since the conduct of the study in Part 2 will be identical to the conduct of the study in Part 1, recruitment will continue uninterrupted. The only potential change between Part 1 and Part 2 are the biomarkers to be measured.
Part 2 is a study with 40 Early PD patients, 10 patients each who are randomized to one of 4 treatment conditions of Posiphen (5 mg, 10 mg, 20 mg, or 40 mg). Participants will undergo a Screening Visit, provide informed consent and be evaluated for eligibility per the inclusion and exclusion criteria. If enrolled, participants will proceed to the randomized treatment portions of the study. Period 1 consists of first-time dosing in clinic with administration of 5, 10, 20, or 40mg of Posiphen. Period 2 consists of an at home dosing period of 25±2 days, with daily administration of 5, 10, 20, or 40mg of Posiphen. Period 3 will be comprised of a stay at the clinical research unit where the subject will undergo study procedures that include safety assessments (AE and concomitant medication monitoring, 12-lead ECGs, clinical laboratory testing, vital signs assessments, and physical examinations), the last dose of Posiphen or Placebo, and 6 hours of blood and CSF sampling. At the end of blood/CSF sampling, the subject will need to stay for a minimum of 1 hour of observation but may stay if necessary for observation until the following day (e.g., if the subject has blood/CSF sampling on Day 25, he/she may stay for observation until Day 26). After all end-of-study procedures are complete, the subject will be discharged to home. A 24-hour follow-up call will occur to assess the participant's current condition and if there are any additional adverse events to report.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet the following criteria:
Stability of permitted medications prior to screening.
i. Anti-parkinsonian medication ii. Anticonvulsant medications used for epilepsy or mood stabilization; neuropathic pain indications iii. Mood-stabilizing psychotropic agents, including, but not limited to, lithium.
Exclusion Criteria
Subjects meeting any of the following criteria must not be included in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
Drug: Posiphen
Posiphen Oral Capsule, 40mg, taken once per day for 25±2 days.
Drug: Posiphen
Posiphen Oral Capsule, 20mg, taken once per day for 25±2 days.
Drug: Posiphen
Posiphen Oral Capsule, 10mg, taken once per day for 25±2 days.
Drug: Posiphen
Posiphen Oral Capsule, 5mg, taken once per day for 25±2 days.
Drug: Posiphen
Placebo Oral Capsule, taken once per day for 25±2 days.
Drug: Placebo
Placebo Oral Capsule, taken once per day for 25±2 days.
Drug: Placebo
Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
Drug: Posiphen
Solid oral dosage form, capsule
Solid oral dosage form, capsule
Percentage of Participants With Treatment-Emergent Adverse Events
Percent of patients with AEs in the Posiphen treatment arms compared to the Placebo group
Time frame: 25±2 days
Concentration of Posiphen in Plasma
Maximum Plasma Concentration (Cmax) of Posiphen reported as ng/mL.
Time frame: Samples collected over a 6 hour timeframe
Change in Abeta42/Abeta40 Ratio
Biomarker related to neurotoxic protein cascade measured in patient sample
Time frame: Baseline to 25±2 days
Changes in Functional Impairment
Functional impairment will be evaluated using the Clinical Dementia Rating (CDR) scale (Berg1988) for AD.
Time frame: Baseline to 25±2 days
Changes in Functional Impairment
Functional impairment will be evaluated using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale (Goetz 2008) for those with PD.
Time frame: Baseline to 25±2 days
Changes in Cognition
For both populations, the Mini-Mental State Examination (MMSE) scale (Folstein 1975) will be administered as a global measure of cognition.
Time frame: Baseline to 25±2 days
Changes in Cognition
For both populations, the Coding subtest from the Weschler Adult Intelligence Scales, 4th edition (WAIS-IV) will serve as a sensitive measure of CNS dysfunction.
Time frame: Baseline to 25±2 days
Changes in Cognition
The subjects with AD will also be administered the The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale (Schafer 2012).
Time frame: Baseline to 25±2 days
| Milestone | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 10 | 11 | 10 | 12 | 5 | 6 | 10 |
| Completed | 9 | 9 | 11 | 9 | 11 | 5 | 5 | 10 |
| Not completed | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 |
Percent of patients with AEs in the Posiphen treatment arms compared to the Placebo group
| Participants | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events | 3 | 5 | 4 | 6 | 1 | 3 | 3 | 5 |
Maximum Plasma Concentration (Cmax) of Posiphen reported as ng/mL.
| ng/mL | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) |
|---|---|---|---|---|---|---|---|---|
| Concentration of Posiphen in Plasma | 94.9 ± 33.4 | 40.2 ± 19.7 | 15.3 ± 21.6 | 2.0 ± 1.4 | 0.4 ± 0.3 | — | — | 112.3 ± 49.3 |
Biomarker related to neurotoxic protein cascade measured in patient sample
Results for this outcome have not been posted.
Functional impairment will be evaluated using the Clinical Dementia Rating (CDR) scale (Berg1988) for AD.
Results for this outcome have not been posted.
Functional impairment will be evaluated using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale (Goetz 2008) for those with PD.
Results for this outcome have not been posted.
For both populations, the Mini-Mental State Examination (MMSE) scale (Folstein 1975) will be administered as a global measure of cognition.
Results for this outcome have not been posted.
For both populations, the Coding subtest from the Weschler Adult Intelligence Scales, 4th edition (WAIS-IV) will serve as a sensitive measure of CNS dysfunction.
Results for this outcome have not been posted.
The subjects with AD will also be administered the The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale (Schafer 2012).
Results for this outcome have not been posted.
Collected over 25±2 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Posiphen, 80mg (Parkinson's Participants) | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Posiphen, 40mg (Parkinson's Participants) | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Posiphen, 20mg (Parkinson's Participants) | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Posiphen, 10mg (Parkinson's Participants) | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Posiphen, 5mg (Parkinson's Participants) | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Placebo (Parkinson's Participants) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Placebo (Alzheimer's Participants) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Posiphen, 80mg (Alzheimer's Participants) | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Event | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) |
|---|---|---|---|---|---|---|---|---|
| back painMusculoskeletal and connective tissue disorders | 0/10 | 1/10 | 0/11 | 1/10 | 0/12 | 2/5 | 1/6 | 1/10 |
| headacheNervous system disorders | 0/10 | 1/10 | 3/11 | 4/10 | 0/12 | 1/5 | 0/6 | 2/10 |
| puncture site painGeneral disorders | 0/10 | 0/10 | 0/11 | 1/10 | 0/12 | 0/5 | 2/6 | 1/10 |
| dizzinessNervous system disorders | 0/10 | 0/10 | 0/11 | 0/10 | 1/12 | 1/5 | 0/6 | 0/10 |
| pain in extremityMusculoskeletal and connective tissue disorders | 0/10 | 0/10 | 0/11 | 1/10 | 0/12 | 1/5 | 0/6 | 0/10 |
| fatigueGeneral disorders | 0/10 | 0/10 | 2/11 | 1/10 | 0/12 | 0/5 | 0/6 | 0/10 |
| aspartate aminotransferase increasedInvestigations | 0/10 | 0/10 | 0/11 | 0/10 | 0/12 | 0/5 | 1/6 | 0/10 |
| electrocardiogram QT prolongationInvestigations | 0/10 | 0/10 | 0/11 | 0/10 | 0/12 | 0/5 | 0/6 | 1/10 |
| liver function test abnormalInvestigations | 0/10 | 0/10 | 0/11 | 0/10 | 0/12 | 0/5 | 0/6 | 1/10 |
| cystitisInfections and infestations | 0/10 | 0/10 | 0/11 | 0/10 | 0/12 | 0/5 | 0/6 | 1/10 |
| Age, Continuous(years) | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 65.0 ± 9.31 | 62.5 ± 6.74 | 69.8 ± 10.93 | 62.0 ± 9.93 | 67.2 ± 6.94 | 75.4 ± 3.13 | 68.0 ± 6.87 | 72.8 ± 6.34 | 67.3 ± 8.84 |
| Sex: Female, Male(Participants) | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 8 | 25 |
| Male | 8 | 8 | 8 | 7 | 10 | 3 | 3 | 2 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 5 | 2 | 3 | 2 | 4 | 5 | 21 |
| Not Hispanic or Latino | 10 | 10 | 6 | 8 | 9 | 3 | 2 | 5 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| White | 10 | 10 | 9 | 10 | 12 | 5 | 4 | 8 | 68 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Posiphen, 80mg (Parkinson's Participants) | Posiphen, 40mg (Parkinson's Participants) | Posiphen, 20mg (Parkinson's Participants) | Posiphen, 10mg (Parkinson's Participants) | Posiphen, 5mg (Parkinson's Participants) | Placebo (Parkinson's Participants) | Placebo (Alzheimer's Participants) | Posiphen, 80mg (Alzheimer's Participants) | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 10 | 10 | 11 | 10 | 12 | 5 | 6 | 10 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Aug 2021, 12 months.
Results were first posted in Feb 2023, 1 year 6 months after primary completion.
Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Buntanetap
Annovis Bio Inc.